Santiago Bullich
Overview
Explore the profile of Santiago Bullich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1026
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jovalekic A, Bullich S, Roe-Vellve N, Kolinger G, Howard L, Elsholz F, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770490
Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who...
2.
Tonietto M, Sotolongo-Grau O, Roe-Vellve N, Bullich S, Tartari J, Sanabria A, et al.
Alzheimers Res Ther
. 2024 Nov;
16(1):257.
PMID: 39605030
Background: Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical...
3.
Collij L, Bollack A, La Joie R, Shekari M, Bullich S, Roe-Vellve N, et al.
Alzheimers Dement
. 2024 Nov;
20(12):9037-9048.
PMID: 39564918
Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium...
4.
Leuzy A, Raket L, Villemagne V, Klein G, Tonietto M, Olafson E, et al.
Alzheimers Dement
. 2024 Jul;
20(9):5833-5848.
PMID: 39041435
Introduction: Tau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer...
5.
Shekari M, Garcia D, Collij L, Altomare D, Heeman F, Pemberton H, et al.
Alzheimers Dement
. 2024 Jul;
20(8):5102-5113.
PMID: 38961808
Introduction: Assessing the potential sources of bias and variability of the Centiloid (CL) scale is fundamental for its appropriate clinical application. Methods: We included 533 participants from AMYloid imaging to...
6.
Villemagne V, Leuzy A, Sanabria Bohorquez S, Bullich S, Shimada H, Rowe C, et al.
Alzheimers Dement (Amst)
. 2023 Jul;
15(3):e12454.
PMID: 37424964
Introduction: Recently, an increasing number of tau tracers have become available. There is a need to standardize quantitative tau measures across tracers, supporting a universal scale. We developed several cortical...
7.
Jovalekic A, Roe-Vellve N, Koglin N, Quintana M, Nelson A, Diemling M, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jun;
50(11):3276-3289.
PMID: 37300571
Purpose: Amyloid positron emission tomography (PET) with [F]florbetaben (FBB) is an established tool for detecting Aβ deposition in the brain in vivo based on visual assessment of PET scans. Quantitative...
8.
Collij L, Salvado G, de Wilde A, Altomare D, Shekari M, Gispert J, et al.
Alzheimers Dement
. 2022 Dec;
19(6):2397-2407.
PMID: 36478646
Introduction: We investigated amyloid-burden quantification in a mixed memory clinic population. Methods: [ F]Florbetaben amyloid-PET (positron emission tomography) scans of 348 patients were visually read and quantified using the Centiloid...
9.
Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, et al.
Alzheimers Res Ther
. 2022 Jul;
14(1):105.
PMID: 35897078
Background: The ability of F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer's disease (AD) has been demonstrated in previous studies. The objective of this work was...
10.
Pemberton H, Collij L, Heeman F, Bollack A, Shekari M, Salvado G, et al.
Eur J Nucl Med Mol Imaging
. 2022 Apr;
49(10):3508-3528.
PMID: 35389071
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo...